1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
    Journal Article

    Ghione, P.; Palomba, M. L.; Patel, A. R.; Bobillo, S.; Deighton, K.; Jacobson, C. A.; Nahas, M.; Hatswell, A. J.; Jung, A. S.; Kanters, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Triggering with 1,500 IU of human chorionic gonadotropin plus follicle-stimulating hormone compared to a standard human chorionic gonadotropin trigger dose for oocyte competence in in vitro fertilization cycles: A randomized, double-blinded, controlled noninferiority trial
    Journal Article

    Anaya, Y.; Cakmak, H.; Mata, D. A.; Letourneau, J.; Zhang, L.; Lenhart, N.; Juarez-Hernandez, F.; Jalalian, L.; Cedars, M. I.; Rosen, M.
    Fertility and Sterility (2022)

    Fulltext@MSK | Save
  • Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): A prospective, randomized, controlled clinical trial
    Journal Article

    Linxweiler, M.; Körner, S.; Wemmert, S.; Rimbach, H.; Helfrich, J.; Linxweiler, B.; Takacs, Z. F.; Solomayer, E. F.; Wagner, M.; Morris, L. G. T.; more...
    European Archives of Oto-Rhino-Laryngology (2022)

    Fulltext@MSK | Save
  • Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma
    Journal Article

    Ansell, S. M.; Radford, J.; Connors, J. M.; Długosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; Hutchings, M.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • An exploratory analysis of the “Was it worth it?” questionnaire as a novel metric to capture patient perceptions of cancer treatment
    Journal Article

    Thanarajasingam, G.; Basch, E.; Mead-Harvey, C.; Bennett, A. V.; Mazza, G. L.; Schwab, G.; Roydhouse, J.; Rogak, L. J.; Dueck, A. C.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: A protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial
    Journal Article

    Hassett, M. J.; Wong, S.; Osarogiagbon, R. U.; Bian, J.; Dizon, D. S.; Jenkins, H. H.; Uno, H.; Cronin, C.; Schrag, D.; Simpro Co-Investigators
    Trials (2022)

    Fulltext@MSK | Save
  • Triplet therapy, transplantation, and maintenance until progression in myeloma
    Journal Article

    Richardson, P. G.; Jacobus, S. J.; Weller, E. A.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
    Journal Article

    Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N. T.; Prat, A.; Chae, Y. S.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
    Journal Article

    Wang, M. L.; Jurczak, W.; Jerkeman, M.; Trotman, J.; Zinzani, P. L.; Belada, D.; Boccomini, C.; Flinn, I. W.; Giri, P.; Goy, A.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save